Serum YKL-40 as a Predictive Biomarker of Cerebral Amyloid Angiopathy-Related Intracerebral Hemorrhage Recurrence
Journal of Alzheimer's Disease · 2024
DOI: 10.3233/jad-231125 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer's Disease, 2024. Verfasst von Feifan Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, National Centre for Neurological Disorders, National Clinical Research Centre for Aging and Medicine, Huashan Hospital, Fuda…. Hauptthemen laut MEDLINE: Chitinase-3-Like Protein 1, Cerebral Amyloid Angiopathy, Biomarkers, Cerebral Hemorrhage. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Background
Neuroinflammation is a major cause of secondary brain injury in intracerebral hemorrhage (ICH). To date, the prognostic value of YKL-40 (chitinase-3-like-1 protein), a biomarker of neuroinflammation, in cerebral amyloid angiopathy-related intracerebral hemorrhage (CAA-ICH) remains undiscovered.
Objective
To evaluate the relationships between serum YKL-40 and CAA-ICH recurrence.
Methods
Clinical and imaging information of 68 first-onset probable CAA-ICH cases and 95 controls were collected at baseline. Serum YKL-40 was measured by Luminex assay. Cox proportional hazards model was used to analyze the associations between YKL-40 level and CAA-ICH recurrence.
Results
Serum YKL-40 level was significantly higher in CAA-ICH cases than healthy controls (median [interquartile range, IQR], 46.1 [19.8, 93.4] versus 24.4 [13.9, 59.0] ng/mL, p = 0.004). Higher level of YKL-40 predicted increased risk of CAA-ICH recurrence adjusted for age, ICH volume and enlarged perivascular space score (ePVS) (above versus below 115.5 ng/ml, adjusted hazard ratios 4.721, 95% confidence intervals 1.829–12.189, p = 0.001) within a median follow-up period of 2.4 years. Adding YKL-40 to a model of only MRI imaging markers including ICH volume and ePVS score improved the discriminatory power (concordance index from 0.707 to 0.772, p = 0.001) and the reclassification power (net reclassification improvement 28.4%; integrated discrimination index 11.0%).
Conclusions
Serum YKL-40 level might be a candidate prognostic biomarker for CAA-ICH recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, National Centre for Neurological Disorders, National Clinical Research Centre for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China.
- Department of Neurology, First Affiliated Hospital of University of Science and Technology of China, Hefei, China.
- Neurodegenerative Disorder Research Centre and Institute on Aging and Brain Disorders, University of Science and Technology of China, Hefei, China.
Zitieren
APA
Xu, F., Xu, J., Wang, Q., Gao, F., Fu, J., Yan, T., Dong, Q., Su, Y., & Cheng, X. (2024). Serum YKL-40 as a Predictive Biomarker of Cerebral Amyloid Angiopathy-Related Intracerebral Hemorrhage Recurrence. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-231125
Vancouver
Xu F, Xu J, Wang Q, Gao F, Fu J, Yan T, et al. Serum YKL-40 as a Predictive Biomarker of Cerebral Amyloid Angiopathy-Related Intracerebral Hemorrhage Recurrence. Journal of Alzheimer's Disease. 2024. doi:10.3233/jad-231125
BibTeX
@article{Xu2024,
author = {Xu, Feifan and Xu, Jiajie and Wang, Qiong and Gao, Feng and Fu, Jiayu and Yan, Tingmeng and Dong, Qiang and Su, Ya and Cheng, Xin},
title = {Serum YKL-40 as a Predictive Biomarker of Cerebral Amyloid Angiopathy-Related Intracerebral Hemorrhage Recurrence},
journal = {Journal of Alzheimer's Disease},
year = {2024},
doi = {10.3233/jad-231125}
}
EUVIMED